Eupraxia Pharmaceuticals (EPRX) Stock: Buy, Sell, or Hold?
EPRX - Eupraxia Pharmaceuticals Inc. Common Stock
$8.40
0.90 (12.00%)
▲
5d:
+25.84%
30d:
+26.13%
90d:
+41.18%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When EPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: EPRX is 15.2% above its trading range ($7.29). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: EPRX is 15.2% above its trading range ($7.29). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: EPRX is currently trading at $8.40, which is considered extended relative to its 30-day fair value range of $6.30 to $7.29.
Technical Outlook: Technically, EPRX is in a downtrend. The price is approaching resistance at $8.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.0% recently.
Market Sentiment: EPRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $16.35 (+94.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EPRX is in a downtrend. The price is approaching resistance at $8.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.0% recently.
Market Sentiment: EPRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $16.35 (+94.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.30 -
$7.29
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+15.2% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.0%)
- BULLISH: Trading 94.6% below Wall St target ($16.35)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.30 -
$7.29
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.33
Resistance Level
$8.40
Current Trend
Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.07
Wall Street Target
$16.35
(+94.6%)
Share & Embed Analysis
Last updated: September 07, 2026 2:06 AM ET
Data refreshes hourly during market hours. Next update: 3:06 AM
Data refreshes hourly during market hours. Next update: 3:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 45 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 46 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 44 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 27 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 57 HOLD |
